The Journal of Pediatrics
Volume 154, Issue 4 , Pages 541-545 , April 2009

Trends in Pediatric Sickle Cell Disease-Related Mortality in the United States, 1983-2002

Received 2 April 2008 ,Revised 3 September 2008 ,Accepted 29 September 2008.

References 

  1. Olney RS. Preventing morbidity and mortality from sickle cell disease: a public health perspective. Am J Prev Med. 1999;16:116–121
  2. Olney R. Newborn screening for sickle cell disease. In:  Khoury M,  Burke W,  Thomson E editor. Genetics and Public Health in the 21st Century. New York: Oxford University Press; 2000;p. 431–446
  3. Centers for Disease Control and Prevention. Mortality among children with sickle cell disease identified by newborn screening during 1990-1994—California, Illinois, and New York. MMWR Morb Mortal Wkly Rep. 1998;47:169–172
  4. Davis H, Schoendorf KC, Gergen PJ, Moore RM. National trends in the mortality of children with sickle cell disease, 1968 through 1992. Am J Public Health. 1997;87:1317–1322
  5. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004;103:4023–4027
  6. Bonds DR. Three decades of innovation in the management of sickle cell disease: the road to understanding the sickle cell disease clinical phenotype. Blood Rev. 2005;19:99–110
  7. Yang YM. Comparison of costs to the health sector of comprehensive and episodic health care for sickle cell disease patients. Public Health Rep. 1995;110:80–86
  8. Centers for Disease Control. Update: Pneumococcal polysaccharide vaccine usage—United States. MMWR Morb Mortal Wkly Rep. 1984;33:273–276281
  9. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med. 1986;314:1593–1599
  10. Consensus conference: newborn screening for sickle cell disease and other hemoglobinopathies. JAMA. 1987;258:1205–1209
  11. Pass KA, Lane PA, Fernhoff PM, Hinton CF, Panny SR, Parks JS, et al. US newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN). J Pediatr. 2000;137:S1–S46
  12. Schoendorf KC, Adams WG, Kiely JL, Wenger JD. National trends in Haemophilus influenzae meningitis mortality and hospitalization among children, 1980 through 1991. Pediatrics. 1994;93:663–668
  13. American Academy of Pediatrics. Red Book: Report of the Committee on Infectious Diseases. 26th edition. Elk Grove Village, IL: American Academy of Pediatrics; 2003;
  14. Anderson RN, Minino AM, Hoyert DL, Rosenberg HM. Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. Natl Vital Stat Rep. 2001;49:1–32
  15. Centers for Disease Control and Prevention. Update: newborn screening for sickle cell disease—California, Illinois, and New York, 1998. MMWR Morb Mortal Wkly Rep. 2000;49:729–731
  16. Frempong T. Newborn screening coupled with comprehensive follow-up reduced early mortality of sickle cell disease in Connecticut. Conn Med. 2007;71:9–12
  17. Halasa NB, Shankar SM, Talbot TR, Arbogast PG, Mitchel EF, Wang WC, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44:1428–1433
  18. Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr. 2003;143:438–444
  19. American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics. 2002;109:526–535
  20. Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, et al. Elimination of racial differences in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine. Pediatr Infect Dis J. 2004;23:726–731
  21. Neuman HB, Wald ER. Bacterial meningitis in childhood at the Children's Hospital of Pittsburgh, 1988-1998. Clin Pediatr (Phila). 2001;40:595–600
  22. Shankar SM, Arbogast PG, Mitchel E, Cooper WO, Wang WC, Griffin MR. Medical care utilization and mortality in sickle cell disease: a population-based study. Am J Hematol. 2005;80:262–270
  23. Grosse SD, Schechter MS, Kulkarni R, Lloyd-Puryear MA, Strickland B, Trevathan E. Models of comprehensive, multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics, in press.
  24. Smith LA, Oyeku SO, Homer C, Zuckerman B. Sickle cell disease: a question of equity and quality. Pediatrics. 2006;117:1763–1770
  25. Goss CH, Rosenfeld M. Update on cystic fibrosis epidemiology. Curr Opin Pulm Med. 2004;10:510–514

 The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The authors declare no potential conflicts of interest, real or perceived.

PII: S0022-3476(08)00861-5

doi: 10.1016/j.jpeds.2008.09.052

The Journal of Pediatrics
Volume 154, Issue 4 , Pages 541-545 , April 2009

Article Tools

* Image Usage & Resolution